$AGEN News

Agenus: Weighing The Clinical Progress Against The Company's Cash

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Agenus Reports Durable Survival And Deep Responses With Botensilimab Plus Balstilimab In Heavily Pretreated Checkpoint-Resistant Melanoma, Including 16.6-Month Median OS and 42% Two-Year Survival

Agenus' Noetik TARIO-2 AI Model Identifies Tumor Microenvironment Signature Predicting 64% Response Rate And Markedly Improved Survival In MSS Metastatic Colorectal Cancer Treated With Botensilimab Plus Balstilimab

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Agenus Announces Publication Of Phase 1b Data Evaluating Botensilimab In Combination With Balstilimab In Patients With Treatment-Refractory HCC

Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Agenus To Present Initial Phase 2 Data For Botensilimab Research Across Colorectal Cancer, Melanoma, And Translational Research At American Society Of Clinical Oncology Annual Meeting May 29 - June 2

Agenus Announces Phase II Data Showing Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab And agenT-797 in PD-1 Refractory Gastroesophageal Cancer; The Study Did Not Meet Its Primary Endpoint Of ORR

Agenus shares are trading higher after the company announced that Phase 2 data from the study evaluating botensilimab and balstilimab in combination with agenT-797 will be presented at the American Association for Cancer Research Annual Meeting 2026 on April 17-22, 2026.

Agenus Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Agenus To Present Chemo-Sparing BOT+BAL Immunotherapy Data In 1L MSS Colorectal Cancer At AACR 2026

Agenus shares are trading higher. The company announced it has triggered the first $20 million contingent payment under its strategic collaboration with Zydus Lifesciences.

Agenus Triggers First $20M Contingent Payment Under Prior Collaboration Deal With Zydus Lifesciences

Agenus Data From Phase 1b C-800-01 Study Evaluating Botensilimab Shows Survival With BOT+BAL Associated With Systemic Inflammation In Blood, Tumor Immune Activity Within Tumor Microenvironment

Agenus To Highlight New Data At AACR-IO Exploring Systemic And Tumor Inflammation Biomarkers With BOT/BAL In Immunologically Cold Tumors

Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript